SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• Prior to administration of RYBREVANT, prime the infusion set with the diluent (either 5% dextrose solution or 0.9% sodium chloride solution).²
• Administer the diluted solution by intravenous (IV) infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.2 micrometer).²
• Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), polyvinylchloride (PVC), polypropylene (PP), or polyethylene (PE).²
• Do not infuse RYBREVANT concomitantly in the same IV line with other agents.²
• A flow regulator is for maintaining the infusion rate in case of gravity infusion and may or may not be part of the infusion set. A flow regulator is not needed for infusion with pumps.³ 
• Please refer to product labeling for complete dosage and administration information.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and DerwentDrug File (and/or other resources, including internal/external databases) was conducted on 23 July 2025.